Early in the COVID-19 Pandemic, our scientists and engineers were asked about whether SARS-CoV-2, the virus that causes COVID-19, posed risk to patients through the manufactured cell therapies they receive. This is of special concern, as the patients we manufacture therapies for are often at higher risk of COVID-19 due to their underlying medical conditions. Now the journal Regenerative Medicine has published a paper written in collaboration between our Germany process development team and our colleagues at Minaris USA - "A risk assessment study of SARS-CoV-2 propagation in the manufacturing of cellular products". Thank you to the authors, Enric Redondo Monte, David O’Neill and Karin M. Abitorabi, for their careful work to look into this issue and support positive patient outcomes.
Download our review paper published in Regenerative Medicine (https://www.futuremedicine.com/doi/full/10.2217/rme-2022-0096)